HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference

Stock News

2025/09/05

HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.

According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.

Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1118480758"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118480758\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118480758?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 08:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118480758","market":"nz","top_or_hot":-1,"title":"HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference","media":"Stock News","content":"<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) to Present Latest Data from Multiple Proprietary Compound Studies at 2025 World Conference on Lung Cancer and CSCO 2025 Annual Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2025-09-05 08:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.</p>\n<p>According to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.</p>\n<p>Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"半新股","start_time":0,"source_url":"","article_id":"1118480758","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118480758","pubTimestamp":1757030911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1587":"次新股","BK1191":"制药","BK4588":"碎股","BK4585":"ETF&股票定投概念","00013":"和黄医药","BK4007":"制药","BK1588":"回港中概股","BK4531":"中概回港概念","HCM":"和黄医药"},"translate_title":"和黄医药(00013)将于2025年世界肺癌大会暨CSCO 2025年年会展示多项专利化合物研究最新数据","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1,"00013":1},"content_text":"HUTCHMED (00013) announced that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held September 6-9, 2025 in Barcelona, Spain, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Conference to be held September 10-14, 2025 in Jinan, China.\nAccording to the announcement, the latest analytical results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.\nData from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Conference.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}